Previous studies reported the HSP90α complex (consisting of different HSP and co-chaperones) from cancer cells revealed a 100-fold greater binding affinity with inhibitors than the homodimeric HSP90α from normal cells. This evidence concerns the gene HSP90B2P and cancer.